Клинико-прогностическая значимость маркеров пролиферативной активности, апоптоза и межклеточной адгезии при плоскоклеточном раке легкого
Диссертация
Учитывая генетическую полиморфность HMPJI и его низкую чувствительность к химиотерапии, высокую токсичность и стоимость применяемых препаратов, целесообразно более точно определять группу пациентов, подлежащих дополнительным видам послеоперационной терапии. Отсутствие данных о параметрах опухоли, характеризующих ее биологическую активностьскорость роста, интенсивность неоваскуляризации… Читать ещё >
Список литературы
- Арсеньев, А. И. Адъювантная химиотерапия и лучевая терапия не-мелкоклеточного рака легкого / А. И. Арсеньев // Практическая онкология. -2006.-№ 3.-С. 154−160.
- Давыдов, М. И. Совершенствование хирургического лечения больных немелкоклеточным раком легкого / М. И. Давыдов, С. М. Вол-ков, Б. Е. Полоцкий //Российский онкологический журнал. — 2001. № 5. — С. 14−17.
- Давыдов, М. И. Современные принципы выбора лечебной тактики и возможность хирургического лечения немелкоклеточного рака легкого // Новое в терапии рака легкого / М. И. Давыдов, Б. Е. Полоцкий. М., 2003. — С. 41 -53.
- Иммуногистохимия биомолекулярных маркеров рака легкого / Е. А. Коган, Г. Жак, У. Кайзер и др. // Архив патологии. 1997.6. С. 23−30.
- Коган, Е. А. Соотношение процессов пролиферации и клеточной гибели в немелкоклеточном раке легкого с железистой дифференцировкой на разных стадиях опухолевой прогрессии / Е. А. Коган, Д. А. Угрюмов // Архив патологии. 2002. — № 1. — С. 33−37.
- Комбинированные операции при немелкоклеточном раке легкого III стадии / А. X. Трахтенберг, Г. А. Франк, К. И. Колбанов и др. // Вестник РОНЦ. -2003. № 1. — С- 50−54.
- Лактионов, К. К. Плоскоклеточный рак легкого (значение клинико-морфологических и молекулярно-генетических характеристик опухоли в прогнозировании результатов хирургического лечения): дис.. д-ра мед. наук / К. К. Лактионов М., 2004. — 259 с.
- Моисеенко, В. М. Лекарственное лечение распространенного немелкоклеточного рака легкого / В. М. Моисеенко // Практическая онкология. -2006. № 3. — С. 154−160, 171−178.
- Моисеенко, В. М. Лекции по фундаментальной и клинической онкологии / В. М. Моисеенко, А. Ф. Урманчеева, К. П. Хансон. СПб., 2004. — С. 17−27, 181−196.
- Ю.Нефробластома — тест-объект детской опухоли Электронный ресурс. / Л. А. Дурнов, Т. А. Шароев, В. И. Лебедев [и др.]. М., 2002. — режим доступа: www.oncology.tomsk.ru/nii/gournal/2002/l/information/soj-2002−1-12−18.pdf.
- Новик, А. А. Введение в молекулярную биологию канцерогенеза / А. А. Новик, Т. А. Камилова, В. А. Цыган. М.: Изд. ГЭОТАР-МЕДИА, 2004. -261 с.
- Пальцев, М. А. Межклеточные взаимодействия. / М. А. Пальцев, А. А. Иванов, С. Е. Северин. 2-е изд., перераб. и доп. — М.: «Медицина», 2003. -182 с.
- Патолого-анатомическая диагностика опухолей человека / под ред. Н. А. Краевский, А. В. Смолянников, Д. С. Саркисов. М., Медици-на, 1993. С. 464−475.
- Полоцкий, Б. Е., Лактионов К. К. Рак легкого Электронный ресурс. Материалы цикла повышения квалификации врачей. Режим доступа: http://www.pror.ru/art-01.shtml. — 2008.
- Прогностические и предсказывающие факторы у больных немелко-клеточным раком легкого / К. К. Лактионов, М. И. Давыдов, Б. Е. Полоцкий и др. // Практическая онкология. 2006. — № 3. — С. 145−153.
- Степанова, Е. В. Экспрессия молекулярно-биологических маркеров при немелкоклеточном раке легкого : дис.. канд. мед. наук / Е. В. Степанова. М., 2002. — 130 с.
- Харченко, В. П. Рак легкого / В. П. Харченко, И. В. Кузьмин. М., Медицина, 1994. — 386 с.
- Чиссов, В.И., Давыдов, М.И. Национальное руководство. Онкология. М., «ГЭОТАР-Медиа», 2008. — С. 631−638.
- Шацева, Т. А. Антиген Ki-67 в оценке опухолевой пролиферации, его структура и функции / Т. А. Шацева, М. С. Мухина // Вопросы онкологии. 2004. — № 2. — С. 157−164.
- Элиниди, В. Н. Практическая иммуноцитохимия (практические рекомендации) / В. Н. Элиниди, Н. В. Аникеева, Н. А. Максимова. СПб.: Изд-во Всероссийского центра экстремальной и радиационной медицины МЧС России, 2002. — 25 с.
- A prognostic model of recurrences and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression / D. H. Harpole, J. E. Herndon, W. G. Wolfe et al. // Cancer Res. 1995. — № 55. — P. 51−56.
- A study of E-cadherin and beta-catenin expression and their correlation with prognosis of non-small cell lung carcinoma / R. T. Pirinen, P. Hirvikoslci, Q. Li et al. // Zhonghua Bing Liu Xue Za Zhi, 2002. 31 (4). — P. 318−321.
- Altered expression of E-cadherin in breast cancer: patterns, mechanismst t t л л лand clinical significance / K. S. AAsgeirsson, J. G. JoAnasson, L. TryggvadoAttir et al. //Eur. J. of Cancer. 2000. — № 36. — P. 1098−1106.
- Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features / Y. Wei, J. T. Van Nhieu, S. Prigent et al. // Hepatology. 2002. — № 36 (3). — P. 692 701.
- Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma / J. Bourhis, R. Lubin, B. Roche et al. // J. Natl. Cancer Inst. 1996. — № 88 (17). — P. 1228−1233.
- Apoptosis, p53, and tumor cell sensitivity to aticancer agents / J. M. Brown, B. G. Wouters // Cancer Research. 1999. — № 59. — P. 1391−1399.
- Assessment of cell proliferation antigen Ki-67, protein p53 related to apoptosis and angiogenesis in laryngeal cancer / M. Gryczynski, J. Kobos, H. Niewiadomska et al. // Otolaryng. Pol. 2000. — 54, suppl. 31. — P. 191−195.
- Association of E-cadherin and beta-catenin immunoexpression with clinico-pathologic features in primary ovarian carcinomas / C. Faleiro-Rodrigues, T. Macedo-Pinto, D. Pereira et al. // Hum. Pathol. 2004. — № 35 (6). — P. 663−669.
- Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma / Z. Li, Y. Ren, S. X. Lin et al // Chin. Med. J. 2004. — № 117(8). — P. 1232−1239.
- Bcl-2 protein: a prognostic factor inverselly correlated to p53 in non-small-cell lung cancer / G. Fontanini, S. Vignati, D. Bigini et al. // Br. J. Cancer. -1995. № 71 (5). — P. 1003−1007.
- Beavon, I. R. The E-cadherin-catenin complex in tumor metastasis: structure, function and regulation / I. R. Beavon // Eur. J. of Cancer. 2000. — Vol. 36. — P. 1607−1620.
- Biological markers in non-small cell lung cancer. Retrospective study of 10-year follow-up after surgery / P. Carbognani, G. Tincani, P. Crafa et al. // J. Cardiovasc. Surg. (Torino). 2002. — № 43 (4). — P. 45−48.
- Biological prognostic factors for early stage completely resected non-small cell lung cancer / L. Cagini, M. Monacelli, G, Giustozzi et al. // J. Surg. Oncol. 2000. — № 74 (1). — P. 53−60.
- Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumors / C. Faleiro-Rodrigues, I. M. Macedo-Pinto, S. S. Maia et al. // Gynecol. Obstet. Invest. 2005. — № 60 (2). — P. 75−83.
- Biomolecular markers of breast cancer / A. Nicolini, A. Carpi, G. Tarro //Front Biosci. 2006. — № 11. — P. 1818−1843.
- C-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study / P. Fritz, С. M. Cabrera, J. Dippon et al. // Breast Cancer Res. 2005. — № 7 (3). — P. 374−384.
- C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adeno-carcinomas / J. A. Kern, R. J. Sle-bos, B. Top et al. // J. Clin. Invest. 1994. — № 93. — P. 516−520.
- Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma / M. Ikeguchi, M. Malcino, N. Kaibara // J. Surg. Oncol. 2001. — № 77 (3). — P. 201−207.
- Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma / O. S. Lam, O. Shvarts, J. W. Said et al. //Cancer. -2005.- № 103 (12).-P. 2517−2525.
- Combined examination of p27(Kipl), p21(Wafl/Cipl) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma / X. P. Liu, S. Kawauchi, A. Oga et al. // Histopathol. 2001. — № 39 (6). — P. 603 610.
- Comparison of DNA topoisomerase II alpha expression in small cell and non-small cell carcinoma of the lung. In search of a mechanism of chemother. response / D. G. Guinee, J. A. Holden, J. R. Benfield et al. // Cancer. 1996. — № 78 (4).-P. 729−735.
- Contribution of c-erbB-2 and topoisomerase Ilalpha to chemoresistance in ovarian cancer / J. G. Hengstler, J. Lange, A. Kett et al. // Cancer Res. 1999. -№ 59 (13). — P. 3206−3214.
- Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma / Y. Tomizawa, T. Kohno, T. Fujita et al. // Oncogene. 1999. — № 18 (4). — P. 1007−1014.
- Correlation between topoisomerase II alpha gene amplification and protein expression in HER-2 amplified breast cancer / V. Durbecq, C. Desmed, M. Paesmans et al. // Int. J. Oncol. 2004. — № 25 (5). — P. 1473−1479.
- Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma / H. Visapaa, M. Bui, Y. Huang et al. // Urology. 2003. — № 61 (4).-P. 845−850.
- Cyclin, Dl, p53, and p21Wafl/Cipl expression as predictive of poor clinical outcome in serous epithelial ovarian cancer / A. Bali, P. M. O’Brien, L. S. Edwards et al. //Clin. Cancer Res. 2004. — № 10 (15). — P. 5168−5177.
- Destructive cycles: the role of genomic instability and adaptation in carcinogenesis /L. S. Brandt, M. Kulesz-Martin // Carcinogenesis. 2004. -. Vol. 25. -№ 11.
- Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma / Z. Li, S. X. Lin, Y. J. Liang // Zhonghua Bing Liu Xue Za Zhi, 2003. -№ 32 (1). P. 25−30.
- Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines / K. Kasahara. Y. Fujiwara, Y. Sugimoto et al. // J. Natl. Cancer Inst. 1992. — № 84 (2). — P. 113 118.
- Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung / G. Giaccone, J. van Ark-Otte, G. Scagliotti et al. // Biochim. Biophys. Acta. 1995. — № 1264 (3). — P. 337−346.
- Disordered beta-catenin expression and E-cadherin/CDHl promoter me-thylation in gastric carcinoma / L. Wang, F. Zhang, P. P. Wu et al. // World J. Gastroenterol. 2006. — № 12 (26). — P. 4228−4231.
- DNA topoisomerase Ilalpha expression and the response to primary chemotherapy in breast cancer / G. MacGrogan, P. Rudolph, I. I. Mascarel et al. // Br. J. Cancer. 2003. — № 89 (4). — P. 666−671.
- DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer / L. Nakopoulou, A. Lazaris, N. Kavantzas et al. //Pathobiology. 2000. — № 68 (3). — P. 137−143.
- Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies / B. Xu, T. Sano, K., Yoshimoto et al. // Endocr. Pathol. 2002. — № 13 (4). — P. 341−351.
- E-cadherin expression in surgically-resected non-small cell lung cancers a clinicopathological study / Y. C. Lee, С. T. Wu, C. S. Chen et al. // Thor. Card. Surg. — 2000. — № 48 (5). — P. 294−299.
- E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas / S. Nakayama, A. Sasaki, H. Mese et al. // Int. J. Cancer. 2001. -№ 93 (5). — P. 667−673.
- E-cadherin-beta-catenin adhesion complex in neuroendocrine tumors of the lung: a suggested role upon local invasion and metastasis / C. Salon, D. Moro, S. Lantuejoul et al. // Hum. Pathol. 2004. — № 35 (9). — P. 1148−1155.
- E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells / U. H. Frixen, J. Behrens, M. Sachs et al. // J. Cell. Biol. 1991. -№ 113.-P. 173−185.
- Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma / E. Oyama, T. Osaki, N. Nose et al. // Anticancer Res. 2000. — № 20(1B). — P. 505−510.
- Expression and implication of Pgp, MRP, LRP, GST-pi, Topo II alpha in tongue squamous cell carcinoma / W. D. Leng, D. Z. Wang, G. Feng et al. // Hua Xi Kou Qiang Yi Xue Za Zhi, 2004. № 22 (1). — P. 23−25.
- Expression and significance of MRP, GST-pi, Topo Ilalpha, and LRP in gastric carcinoma. / D. Q. Yu, Y. F. Yi // Ai Zheng. 2003. — № 22 (5). — P. 496 499.
- Expression and significance of P-glycoprotein, glutathione S-transferase-pi and topoisomerase II in gastric carcinomas / F. Qin, X. Qin, X. Zhang et al. // Ai Zheng. 2002. — № 21 (2). — P. 167−170.
- Expression correlation of Ki67 to p53, VEGF, and C-erbB-2 genes in breast cancer and their clinical significances / B.J. Li, Z. H. Zhu, J. Y. Wang et al. // Ai Zheng. 2004. — № 23 (10). — P. 1176−1179.
- Expression of c-erbB-2 and topoisomerase Ilalpha in relation to chemo-resistance in ovarian cancer. / B. Tanner, H. Pilch, U. Schaffer et al. // Zentralbl. Gynekol. 2002 Mar. — № 124(3). — P. 176−183.
- Expression of cyclin Dl, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2 / V. N. Nguyen, P. Mirejovsky, L. Melinova et al. // Acta Histochem. 2000. — № 102 (3). — P. 323 338.
- Expression of cyclins D3, Bl, oncoprotein Rb and Ki67 proliferation index in non-small cell lung cancer. / S. Xynogalos, C. Lariou, Ch. Vamvouka et al. // ASCO Ann. Meet., 2002. P. 192−194.
- Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa / S. Hirata, O. Katoh, T. Oguri et al. // Jpn. J. Cancer Res. 2000. — № 91 (1). — P. 84−90.
- Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival / Y. N. Zhou, C. P. Xu, B. Han et al. // World J. Gastroenterol. 2002. — № 8 (6). — P. 987−993.
- Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance / S. Kase, K. Sugio, K. Yamazaki et al. // Clin. Cancer Res. 2000. — № 6 (12). — P. 4789−4796.
- Expression of E-cadherin and catenins in early gastric cancer / Y. E. Joo, J. S. Rew, S. K. Choi et al. // J. Clin. Gastroent. 2002. — № 35 (1). — P. 3542.
- Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer / P. Lipponen, E. H. Saarelainen, S. Aaltomaa et al. // J. Pathol. 1994. — № 174. — P. 101−109.
- Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer / S. Ishikawa, T. Nakagawa, R. Miyahara et al. // Clin. Cancer Res. 2005. — № 11 (3). — P. 1198−1202.
- Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines / S. Hasegawa, T. Abe, S. Naito et al. // Br. J. Cancer. 1995. — № 71 (5). — P. 907 913.
- Expression of surviving and proliferating cell nuclear antigen in human non-small cell lung cancer / J. M. Zhou, J. H. Zhou, Z. H. Deng et al. // Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005. — № 30 (5). — P. 544−548.
- Expression of the E-cadherin-catenin complex in lung neuroendocrine tumors / С. E. Clavel, F. Nollet, G. Berx et al. // J. Pathol. 2001. — № 194 (1). -P. 20−26.
- Expression of topoisomerase Ilalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer / T. A. Jarvinen, J. Kononen, M. Pelto-Huikko et al. // Am. J. Pathol. 1996. — № 148 (6). — P. 20 732 082.
- Expression of Y box-binding protein-1 correlates with DNA topoisomerase Ilalpha and proliferating cell nuclear antigen expression in lung cancer / C. Gu, T. Oyama, T. Osaki et al. // Anticancer Res. -2001.- 21 (4A). P. 23 572 362.
- High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small cell lung cancer / R. M. Bremnes, R. Veve, E. Gabrielson et al. // Cancer. 2002. — № 94 (2). — P. 386 392.
- Immunohistochemical and twoparameter flow cytometric studies of DNA topoisomerase Ilalpha in human epithelial ovarian carcinoma and germ cell tumor / K. Tanoguchi, H. Sasano, N. Yabuki et al. // Mod. Pathol. 1998. — № 11 (2).-P. 186−193.
- Immunohistochemical examinations (Ki67, p53, nm23) and DNA cyto-photometry in bladder cancer / F. S. Krause, G. Feil, К. H. Bichler // Anticancer Res. 2000. — 20 (6D). — P. 5023−5028.
- Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors / F. R. Marques, G. A. Fonsechi
- Immunohistochemical examinations (Ki67, p53, nm23) and DNA cyto-photometry in bladder cancer Text. / F. S. Krause, G. Feil, К. H. Bichler // Anticancer Res. 2000. — 20 (6D). — P. 5023−5028.
- Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors Text. / F. R. Marques, G. A. Fonsechi-Carvasan, L. A. De Angelo Andrade [et al.] // Gynecol. Oncol. 2004. -№ 94(1).-P. 16−24.
- Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis Text. / W. FIilbe, S. Dirnhofer, F. Oberwasserlechner [et al.] // J. Clin. Pathol. -2003. № 56 (10). — P. 736−741.
- Increased expression of mutant forms of p53 oncogene in primary lungicancer Text. / R. Iggo, K. Gatter, J. Bartek [et al.] // Lancet. 1990. — 335 (8691). -P. 675−679.
- Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line Text. / Y. Matsumoto, K. Kunishio, S. Nagao // J. Neurooncol. 1999. — № 45 (1). — P. 37−46.
- Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells Text. / Z. Li, S. X. Lin, Y.J. Liang / Zhonghua Zhong Liu Xue Za Zhi, 2003.-№ 25 (3). -P. 238−242.
- Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta catenin Text. / Y. Kudo, S. Kitajima, I. Ogawa [et al.] // Clin. Cancer Res. № 10 (16). — P. 5455−5463.
- Ki-67 index exchange the prognostic accuracy of the urothelial superficial bladder carcinoma risk g^oup classification Text. / L. Santos, T. Amaro, C. Costa [et al.] // Int. J. Cancer. 2003. — № 105 (2). — P. 267−272.
- Ki-67 MIB1 labelling index and the prognosis of primary TaTl urothelial cell carcinoma of the bladder Text. / A. Quintero, J. Alvarez-Kindelan, R. J. Luquc [et al.] // J. Clin. Pathol. 2006. — № 59 (1). — P. 83−88.
- Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592 Text. / J. H. Schiller, S. Adak, R. H. Feins [et al.] // J. Clin. Oncol. 2001. — № 19 (2). — P. 448−449.
- Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathological and immunohistochemical study Text. / H. Raybaud-Diogene, A. Fortin, R. Morency [et al.]'// J. Clin. Oncol. 1997. — № 15 (3). — P. 1030−1038.
- Moul, J. W. Angiogenesis, p53, bcI-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy Text. / J. W. Moul // Eur. Urol. 1999. — № 35 (5−6). — P. 399−407.
- Mutations in exon 7 and 8 of p53 as pbor prognostic factors in patients* with non-small cell lung cancer Text. / C. Huang, T. Talci, M. Adachi [et al.] // Oncogene. 1998. — № 16 (19). — P. 2469−2477.
- Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer Text. / T. Mitsudomi, T. Oyama, T. Kusano [et al.] //J. Natl. Cancer Inst. 1993.-№ 85. — P. 2018−2023.
- Neutral-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients Text. / T. Nakashima, C. Huang, D. Liu [et al.] // Br. J. Cancer. 2003. — № 88 (11). — P. 1727−1733.
- Oncogenes and male breast carpinoma: c-erb B-2 and p53 coexpression predicts a poor survival Text. / A. Pich, E. Margaria, L. Chiusa // J. Clin.Oncol. -2000.-№ 18 (16). P. 2948−2956.
- Hashimoto, Y. Tokuchi, M. Hayashi et al. // Cancer Res. 1999. — № 59 (21). — P. 572−577.
- Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody Text. / I. N. Soomro, J. Holmes, W. F. Whimster // Рак. Med. Assoc. 1998. — № 48 (3). — P. 66−69.I
- Predictive survival markers in patients with surgically resected non-small cell lung carcinoma Text. / J. Moldvay, P. Scheid, P. Wild [et al.] // Clin. Cancer Res. 2000. — № 6 (3). — P. 1125−1134.
- Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence Text. / C. Pfister, L. Moore, P. Allard [et, al.] // Clin. Cancer Res. 1999. — № 5 (12). — P. 4079−4084.
- Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer Text. / R. Komaki, L. Milas, J. Y. Ro [et al.] // Int. J. Radiat. Oncol. Biol .Phys. 1998. — № 40 (4). — P. 787−796.
- Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer Text. / R. S. Lai, J. S. Wang, H. K. Hsu [et al.] // Jpn. J. Clin. Oncol. 2002. — № 32 (10). — P. 393−397.
- Prognostic factors in non-small cell lung cancer: a decade of progress Text. / M. D. Brundage, D. Davies, W. J. Mackillop // Chest. 2002. f — № 122. -P. 1037−1057.
- Prognostic rclevance of cell proliferation in head and neck tumors Text. / A. Pich, L. Chiusa, R. Navone // Ann. Oncol. 2004. — № 15 (9). — P. 1319−1329.
- Prognostic releavance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer Text. / D. Dworakowska, S. Gozdz, E. Jassem [et al.] // Lung Cancer. 2002. — № 35 (1). — P. 35−41.
- Prognostic significance of dyscadherin expression in patients with non-small cell lung cancer Text. / M. Tamura, Y. Ohta, Y. Tsunezuka [et al.] // J. Tho-rac. Cardiovasc. Surg. 2005. — № 130 (3). — P. 740−745.
- Prognostic significance of Е-cadherin and beta-catenin in resected stage I non-small cell lung cancer Text. / Y. S. Choi, Y. M. Shim, S. H. Kim [et al.] // Eur. J. Cardiothor. Surg. 2003 — № 24 (3). — P. 441−449.
- Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers Text. / F. Grossi, M. Loprevite, M. Chiaramondia [et al.] // Eur. J. Cancer. 2003. — № 39 (9). — P. 1242−1250.
- Prognostic significance of p53 and bcl-2 abnormalities in operable non-small ccll lung cancer Text. / J. Laudanski, W. Niklinska, T. Burzykowski [et al.] // Eur. Respir J. 2001. — № 17 (4). — P. 660−666.
- Prognostic significance of p53 and ras, p21 expression in non-small celllung cancer Text. / M. Fujino, H. Dosaka-Akita, M. Harada [et al.] // Cancer. -1995. № 76 (12). — P. 2457−2463.
- Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer Text. / Y., Horio, T. Takahashi, T. Kuroishi [et al.] // Cancer Res. 1993. — № 53. — P. 1−4.
- Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer Text. / N. E. Stavropoulos, I. Filiadis, E. Ioachim [et al.] // Anticancer Res. 2002. № 22 (6B). — P. 3759−3764.
- Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma Text. / M. H. Bui, H. Visapaa, D. Seligson [et al.] //J. Urol. 2004. -№ 171. — P. 2461−2466.
- Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell, lung cancer Text. / H. Han, R. J. Landreneau, T. S. Santucci [et al.] // Hum. Pathol. 2002. — № 33 (1). — P. 105−110.
- Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients Text. / N. Falette, M. P. Paperin, L. Treilleux [et al.] //CancerRes. 1998. -№ 58. — P. 1451−1455.
- Prognostic value of serum p53 antibodies in patients with resected non-j small cell lung cancer Text. / J. Laudanski, T. Burzykowski, W. Niklinska [et al.] // Lung. Canccr. 1998. — № 22 (3). — P. 191−200.
- Proliferative status is a risk index for recurrence in primary superficial (pTa/Tl) low-grade urothelial bladder carcinoma Text. / J. S. Su, K. Arima, M. I-Iasegawa [et al.] // Hinyokika ICiyo. 2003 Nov. — № 49 (11). — P. 649−658.
- Reduced E-cadherin expression is associated with increased lymph node1, metastasis and unfavorable prognosis in non-small cell lung cancer. Text. / M. A.
- Sulzer, M. P. Leers, J. A. van Noord et al. // Am. J. Respir. Crit. Care Med. 1998
- Apr.-№ 157 (4 Pt 1).-P. 1319−1323.
- Rcduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival Text. / C. Charpin, S. Garcia, P. Bonnier [et al.] //Am. J. Clin. Pathol. 1998. — № 109. — P. 431−438.
- Reduced expression of E-cadherin in oral squamous cell carcinoma: relationship with DNA methylation of 5' CpG island Text. / Y. Saito, II. Takazawa, K. Uzawa [et al.] // Int. J. Oncol. 1998. — № 12 (2). — P. 293−298.
- Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm Text. / A. Pich, E. Margaria, L. Chiusa [et al.] // Oncol. Rep. 2003. — № 10 (5). — P. 1329−1335.
- Relationship between cancer cell proliferation, tumor angiogenesis and 201T1 uptake in non-small cell lung cancer Text. / S. Fujita, S. Nagamachi, R. Nishii [et al.] //Nucl. Med. Commun. 2006. — № 27 (12). — P. 989−997.
- Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Text. / C. Poleri, J. L. Morero, B. Nieva [et al.] // Chest. -'2003 Jun. № 23 (6). — P. 18 581 867.
- Separating favorable from unfavorable prognostic markers in breast canccr: the role of E-cadherin Text. / R. Heimann, L. Fusheng, R. McBride [et al.] // Cancer research, 2000. № 1560. — P. 298−304.
- The clinical significance of p53, p21, and p27 expressions in rectal carcinoma Text. / B. Lebe, S. Sarioglu, S. Sokmen [et al.] // Appl. Imm. Mol. Morph. -2005. -№ 13 (1). P. 38−44.
- The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma a comparative study with 201T1 Text. / S. i Nagamachi, S. Jinnouchi, K. Nabeshima [et al.] //Neuroradiology. — 2001. — № 43 (12). — P. 1023−1030.
- The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis Text. / R. M. Bremnes, R. Veve, F. R. Hirsch [et al.] // Lung Cancer. 2002. — P. 115−124.
- The expression of beta-catenin in non-small-cell lung cancer: a clinico-pathological study Text. / J. M. Retera, M- P. Leers, M. A. Sulzer [et al.] // J. Clin. Pathol. 1998. — № 51 (12). — P. 891−894.i
- The prognostic significance of p53, p27 kipl, p21 wafl, HER-2/neu, and1
- Ki67 proteins expression in gastric cancer: a clinicopathological and immunohisto-' chemical study of 121 Arab patients Text. / M. S. Al-Moundhri, Y. Nirmala, I. Al-Hadabi [et al.] // J. Surg.Oncol. 2005. — № 91 (4). — P. 243−252.
- The prognostic value of p53 and c-erb B-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma Text. / O. Erdem, A. Dursun, U. Coskun [et al.] // Tumor. 2005. — № 91 (1). — P. 46−52.
- The role of E-cadherin expression in non-small cell lung cancer Text. / S. C. Lim, I. G. Jang, Y. C. Kim [et al.] // J. Korean Med. Sci. 2000. — № 15 (5). -P. 501−505.
- Tonato, M. Final report of the Adjuvant Lung Project Italy (ALPI): an Italian/EORTC-LCG randomised trial of adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC) Text. // ASCO Annual Meeting., 2002.
- Topoisomerase II alpha and other drug resistance markers in advanced non-small cell lung cancer Text. / A. C. Dingemans, J. van Ark-Otte, S. Span [et al.] // Lung. Cancer. 2001. — № 32 (2). — P. 117−128.
- Topoisomerase II alpha expression in breast cancer: correlation with outcome variables Text. / P. L. Depowski, S. I. Rosenthal, T. P. Brien [et al.] // Mod. Pathol. 2000. — № 13 (5). — P. 542−547.
- Topoisomerase II alpha expression in ductal carcinoma in situ of the breast: a preliminary study Text. / B. Shpitz, Y. Bomstein, T. Zehavi [et al.] // I-Ium. Pathol. 2000. — № 31 (10). — P. 1249−1254.
- Topoisomerase II alpha gene expression is regulated by the p53 tumor suppressor gene in non-small cell lung carcinoma patients Text. / D. Liu, C. L. Huang. K. Kameyama [et al.] // Cancer. 2002. — № 94 (8). — P. 2239−2247.
- Using tumor markers to predict the survival of patients with metastatictrenal cell carcinoma Text. / H. L. Kim, D. Seligson, X. Liu [et al.] // J. Urol. -2005.-№ 173(5).-P. 1496−1501.
- Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma Text. / N. Rioux-Leclercq, B. Turlin, J. Bansard [et al.] // Urology. 2000. — № 55 (4). — P. 501−505.
- VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma Text. / C. R. Santos, M. Rodriguez-Pinilla, F. M. Vega [et al.] // Mol. Cancer Res. D 2006. — № 4(3). — P. 177−185.1. Рис.1
- Умереннодифференцированный плоскоклеточный рак легкого (эозин гематоксилин хЮО)1. Рис.2
- Плоскоклеточный рак легкого (иммуногистохимический маркер Ki67 xlOO) k • ЯШ* Vл «V Ф'-i^' Г- Г» «-mm1. Рис.3
- Плоскоклеточный рак легкого (иммуногистохимический маркер р53×400)1. Рис.4
- Плоскоклеточный рак легкого (иммуногистохимический маркер Е-кадхерин х400)1. Рис.5
- Плоскоклеточный рак легкого (иммуногистохимический маркер Ki67×400)